Clinical and morphological effects of hyperbaric oxygen therapy in patients with interstitial cystitis associated with fibromyalgia

Gerardo Bosco, Edoardo Ostardo, Alex Rizzato, Giacomo Garetto, Matteo Paganini, Giorgio Melloni, Giampiero Giron, Lodovico Pietrosanti, Ivo Martinelli, Enrico Camporesi, Gerardo Bosco, Edoardo Ostardo, Alex Rizzato, Giacomo Garetto, Matteo Paganini, Giorgio Melloni, Giampiero Giron, Lodovico Pietrosanti, Ivo Martinelli, Enrico Camporesi

Abstract

Background: Interstitial Cystitis (IC) is a debilitating disorder of the bladder, with a multifactorial and poorly understood origin dealing with microcirculation repeated damages. Also Fibromyalgia (FM) is a persistent disorder whose etiology is not completely explained, and its theorized alteration of pain processing can compromise the quality of life. Both these conditions have a high incidence of conventional therapeutic failure, but recent literature suggests a significant beneficial response to Hyperbaric Oxygen Therapy (HBOT). With this study, this study we evaluated the effects of HBOT on quality of life, symptoms, urodynamic parameters, and cystoscopic examination of patients suffering from both IC and FM.

Methods: We structured an observational clinical trial design with repeated measures (questionnaires, urodynamic test, and cystoscopy) conducted before and 6 months after a therapeutic protocol with hyperbaric oxygen for the treatment of patients suffering from both IC and FM. Patients were exposed to breathing 100% oxygen at 2 atm absolute (ATA) in a multiplace pressure chamber for 90 min using an oro-nasal mask. Patients undertook a cycle of 20 sessions for 5 days per week, and a second cycle of 20 sessions after 1 week of suspension.

Results: Twelve patients completed the protocol. Changes after HBOT were not significant, except for hydrodistension tolerance (mean pre-treatment: 409.2 ml; mean post-treatment: 489.2 ml; p < 0.05). A regression of petechiae and Hunner's ulcers was also noted 6 months after the completion of HBOT.

Conclusions: Our study showed no improvement of symptoms, quality of life, and urodynamic parameters, except for hydrodistension, and a slight improvement in cystoscopic pattern. However, to date, we could not demonstrate the significance of overall results to justify the use of HBOT alone in patients with IC and FM. This observation suggests that additional studies are needed to better understand if HBOT could treat this subset of patients.

Trial registration: NCT03693001 ; October 2, 2018. Retrospectively registered.

Keywords: Fibromyalgia; Hyperbaric medicine; Interstitial cystitis.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow-chart of experimental design. Eligibility and recruitment of patients. Details are reported in the text

References

    1. Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Waxell T, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002;60:573–578. doi: 10.1016/S0090-4295(02)01829-0.
    1. Yang CC, Miller JL, Omidpanah A, Krieger JN. Physical examination for men and women with urologic chronic pelvic pain syndrome: a MAPP (multidisciplinary approach to the study of chronic pelvic pain) network study. Urology. 2018;116:23–29. doi: 10.1016/j.urology.2018.03.021.
    1. Clemens JQ, Meenan RT, Rosetti MC, et al. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 2005;173:98. doi: 10.1097/01.ju.0000146114.53828.82.
    1. Tanaka T, Nitta Y, Morimoto K, Nishikawa N, Nishihara C, Tamada S, et al. Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. BMC Urol. 2011;11:11. doi: 10.1186/1471-2490-11-11.
    1. van Ophoven A, Rossbach G, Oberpenning F, Hertle L. Hyperbaric oxygen for the treatment of interstitial cystitis: long-term results of a prospective pilot study. Eur Urol. 2004;46:108–113. doi: 10.1016/j.eururo.2004.03.002.
    1. Lee J-D, Lee M-H. Increased expression of hypoxia-inducible factor-1α and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology. 2011;78:971.e11–971.e15. doi: 10.1016/j.urology.2011.05.050.
    1. Loran OB, Siniakova LA, Seregin AV, Mitrokhin AA, Plesovskiĭ AM, Vinarova NA. Hyperbaric oxygenation in the treatment of patients with interstitial cystitis: clinical and morphological rationale. Urologiia. 2011;3:3–5.
    1. Mathers MJ, Lazica DA, Roth S. Non-bacterial cystitis: principles, diagnostics and etiogenic therapy options. Aktuelle Urol. 2010;41:361–368. doi: 10.1055/s-0030-1262615.
    1. Binder I, Rossbach G, Van Ophoven A. Die komplexität chronischer beckenschmerzen am beispiel der interstitiellen zystitis. Teil 2: Therapie. Aktuelle Urologie. 2008;39:289–297. doi: 10.1055/s-2008-1038199.
    1. Sutherland AM, Clarke HA, Katz J, Katznelson R. Hyperbaric oxygen therapy: a new treatment for chronic pain? Pain Pract. 2016;16:620–628. doi: 10.1111/papr.12312.
    1. He D-L. AB098. Progress in diagnosis and treatment of bladder pain syndrome/interstitial cystitis. Transl Androl Urol. 2015;4(Suppl 1). 10.3978/j.issn.2223-4683.2015.s098.
    1. Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol. 2010;184:1358–1363. doi: 10.1016/j.juro.2010.06.005.
    1. Efrati S, Golan H, Bechor Y, Faran Y, Daphna-Tekoah S, Sekler G, et al. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome--prospective clinical trial. PLoS One. 2015;10:e0127012. doi: 10.1371/journal.pone.0127012.
    1. Arnold LM, Clauw DJ, McCarberg BH. FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011;86:457–464. doi: 10.4065/mcp.2010.0738.
    1. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–610. doi: 10.1002/acr.20140.
    1. Wolfe F, Häuser W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med. 2011;43:495–502. doi: 10.3109/07853890.2011.595734.
    1. Yildiz Ş, Kiralp M, Akin A, Keskin I, Ay H, Dursun H, et al. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. J Int Med Res. 2004;32:263–267. doi: 10.1177/147323000403200305.
    1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–67. doi: 10.1016/j.eururo.2007.09.019.
    1. Brewer ME, White WM, Klein FA, Klein LM, Waters WB. Validity of pelvic pain, urgency, and frequency questionnaire in patients with interstitial cystitis/painful bladder syndrome. Urology. 2007;70:646–649. doi: 10.1016/j.urology.2007.06.1089.
    1. Jones KD, Maxwell C, Mist SD, King V, Denman MA, Gregory WT. Pelvic floor and urinary distress in women with fibromyalgia. Pain Manag Nurs. 2015;16:834–840. doi: 10.1016/j.pmn.2015.06.001.
    1. O’Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58–63. doi: 10.1016/S0090-4295(99)80333-1.
    1. Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O’leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001;57(6 Suppl 1):62–66. doi: 10.1016/S0090-4295(01)01126-8.
    1. Ito T, Tomoe H, Ueda T, Yoshimura N, Sant G, Hanno P. Clinical symptoms scale for interstitial cystitis for diagnosis and for following the course of the disease. Int J Urol. 2003;10(Suppl):S24–S26. doi: 10.1046/j.1442-2042.10.s1.7.x.
    1. Nordling J, Anjum FH, Bade JJ, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC) Eur Urol. 2004;45(5):662–669. doi: 10.1016/j.eururo.2003.11.021.
    1. Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41:247–252.
    1. Minami A, Tanaka T, Otoshi T, Kuratsukuri K, Nakatani T. Hyperbaric oxygen significantly improves frequent urination, hyperalgesia, and tissue damage in a mouse long-lasting cystitis model induced by an intravesical instillation of hydrogen peroxide. Neurourol Urodyn. 2019;38(1):97–106. doi: 10.1002/nau.23822.
    1. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol. 2009;106:988–995. doi: 10.1152/japplphysiol.91004.2008.
    1. Gandhi J, Seyam O, Smith NL, Joshi G, Vatsia S, Khan SA. Clinical utility of hyperbaric oxygen therapy in genitourinary medicine. Med Gas Res. 2018;8:29–33. doi: 10.4103/2045-9912.229601.
    1. Tamaki M, Saito R, Ogawa O, Yoshimura N, Ueda T. Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. J Urol. 2004;172:945–948. doi: 10.1097/01.ju.0000135009.55905.cb.
    1. Bosco G, Yang Z, Nandi J, Wang J, Chen C, Camporesi EM. Effects of hyperbaric oxygen on glucose, lactate, glycerol and anti-oxidant enzymes in the skeletal muscle of rats during ischaemia and reperfusion. Clin Exp Pharmacol Physiol. 2007;34:70–76. doi: 10.1111/j.1440-1681.2007.04548.x.
    1. Wenzler DL, Gulli F, Cooney M, Chancellor MB, Gilleran J, Peters KM. Treatment of ulcerative compared to non-ulcerative interstitial cystitis with hyperbaric oxygen: a pilot study. Ther Adv Urol. 2017;9:263–270. doi: 10.1177/1756287217731009.
    1. Maeda D, Akiyama Y, Morikawa T, KunitaA OY, Katoh H, et al. Hunner-type (classic) interstitial cystitis: a distinct InflammatoryDisorder characterized by Pancystitis, with FrequentExpansion of clonal B-cells and EpithelialDenudation. PLoS One. 2015;10(11):e0143316. doi: 10.1371/journal.pone.0143316.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir